Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 160 companies set new 52-week lows.
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
IGM Biosciences And ADC Therapeutics Announce Clinical Collaboration Agreement To Evaluate Imvotamab In Combination With ZYNLONTA In Patients With Relapsed Or Refractory B Cell Non-Hodgkin’s Lymphoma
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL –
– Phase 1 Trial
ADC Therapeutics Announced Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals
ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.
JP Morgan Initiates Coverage On ADC Therapeutics with Overweight Rating, Announces Price Target of $5
JP Morgan analyst Brian Cheng initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating and announces Price Target of $5.
